ArticleCurrent microbiology2026
Nanoemulsion-Mediated Suppression of Multidrug-Resistant Klebsiella pneumoniae via Oxygen Consumption Reduction and Biofilm Inhibition.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In this study, seven water‑in‑oil (W/O) nanoemulsion (NE) (NE-21 to NE-27) were developed via high-pressure microfluidization (100-500 nm droplets, Zeta-potential - 3.6 to + 64.5 mV) The formulations comprised sunflower, castor, or olive oils, non‑ionic surfactants Tween‑60 and Brij‑30 (6-8%), cetylpyridinium chloride (1%), and active agents including silver nanoparticles (0.05%) and sodium hypochlorite (2.5%). From over thirty preliminary formulations, seven were selected based on physicochemical stability, with no phase separation observed over seven days at 25 °C. Then evaluated against Klebsiella pneumoniae reference strains (ATCC 35657, MTCC 432) and clinical multidrug‑resistant (MDR) Klebsiella spp. clinical isolates (CI-1 to CI-3). NE-25/NE-26 showed notable antimicrobial activity (MIC 40-94 µg/mL, 45-106 × dilutions), rapid bactericidal action (30 min), 83.92% biofilm inhibition, and metabolic suppression (OCR 0.11 nmol mL⁻
Indexed as
Identifiers
42530666What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.